Provided by Tiger Fintech (Singapore) Pte. Ltd.

Perspective Therapeutics

1.96
-0.0900-4.39%
Pre-market: 1.90-0.0600-3.06%07:37 EDT
Volume:1.18M
Turnover:2.34M
Market Cap:145.14M
PE:-1.65
High:2.04
Open:2.01
Low:1.91
Close:2.05
Loading ...

Perspective Therapeutics Q3 2024 GAAP EPS $(0.21), Inline, Sales $369.000K Beat $172.125K Estimate

Benzinga
·
13 Nov 2024

Perspective Therapeutics: Q3 Earnings Snapshot

Associated Press Finance
·
13 Nov 2024

Press Release: Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Dow Jones
·
13 Nov 2024

Perspective Therapeutics management to meet virtually with Cantor Fitzgerald

TIPRANKS
·
05 Nov 2024

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results

GlobeNewswire
·
31 Oct 2024

UBS launches SMID cap biotechs with cancer, autoimmunity in focus

seekingalpha
·
25 Oct 2024

UBS Initiates Perspective Therapeutics at Buy With $20 Price Target

MT Newswires Live
·
24 Oct 2024

Perspective Therapeutics Price Target Maintained With a $20.00/Share by Wedbush

Dow Jones
·
24 Oct 2024

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

GlobeNewswire
·
23 Oct 2024

Perspective Therapeutics (CATX) Gets a Buy from Truist Financial

TIPRANKS
·
17 Oct 2024

Perspective Therapeutics Makes First Shipment of Investigational Products From New Jersey Facility

MT Newswires Live
·
16 Oct 2024

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

GlobeNewswire
·
16 Oct 2024

Top Midday Decliners

MT Newswires Live
·
12 Oct 2024

Maintained Buy Rating on CATX Amid Adjusted Success Probabilities and Clinical Hurdles

TIPRANKS
·
12 Oct 2024

Buy Rating Affirmed for Perspective Therapeutics Amid Promising Early-Stage Drug Results for Melanoma Treatment

TIPRANKS
·
12 Oct 2024

Perspective Therapeutics Price Target Maintained With a $22.00/Share by Oppenheimer

Dow Jones
·
12 Oct 2024

Perspective Therapeutics Shares Fall After Melanoma Study Data Analysis

Dow Jones
·
12 Oct 2024

Wedbush Adjusts Price Target on Perspective Therapeutics to $20 From $25, Maintains Outperform Rating

MT Newswires Live
·
12 Oct 2024

Dow Surges 150 Points; JPMorgan Posts Upbeat Earnings

Benzinga
·
11 Oct 2024

Perspective Therapeutics Inc trading resumes

TIPRANKS
·
11 Oct 2024